Merck & Co., Inc.
Merck & Co., Inc. reported 13 US-listed holdings worth $526.4 million in its 13F for the quarter ended 30 June 2026, filed 7 August 2026. Its largest: Personalis Inc. (35.8%), Moderna, Inc. (30.7%) and Kymera Therapeutics Inc. (16.8%). Against the quarter before, it opened 3 positions, added to 0, trimmed 0 and sold out of 4.
The 13 largest of its 13 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +106.0% over the 6 quarters to 30 June 2026, against +27.4% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 3
- Entrada Therapeutics Inc. TRDA$12.8 million
- Sutro Biopharma Inc. STRO$9.0 million
- Evaxion Biotech A/S ADR EVAX$3.8 million
Sold out of 4
- Entrada Therapeutics Inc.$22.0 million last quarter
- Sutro Biopharma Inc.$6.8 million last quarter
- Evaxion Biotech A/s$4.5 million last quarter
- Carisma Therapeutics Inc. CARM$47,880 last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Personalis Inc. PSNL | 14.0M | $188.2 million | 35.75% | no change |
| Moderna, Inc. MRNA | 2.3M | $161.6 million | 30.71% | no change |
| Kymera Therapeutics Inc. KYMR | 772.2K | $88.5 million | 16.82% | no change |
| Aktis Oncology Inc. AKTS | 952.8K | $30.7 million | 5.83% | no change |
| Eikon Therapeutics Inc. EIKN | 1.7M | $21.7 million | 4.13% | no change |
| Entrada Therapeutics Inc. TRDA | 1.7M | $12.8 million | 2.43% | new |
| Sutro Biopharma Inc. STRO | 272.4K | $9.0 million | 1.72% | new |
| Alector Inc. ALEC | 3.5M | $7.1 million | 1.35% | no change |
| Evaxion Biotech A/S ADR EVAX | 1.2M | $3.8 million | 0.71% | new |
| Viridian Therapeutics Inc. VRDN | 93.4K | $1.7 million | 0.33% | no change |
| Xilio Therapeutics Inc. XLO | 106.0K | $1.0 million | 0.19% | no change |
| Tuhura Biosciences Inc. HURA | 19.4K | $45,501 | 0.01% | no change |
| Neuphoria Therapeutics Inc. NEUP | 10.0K | $43,818 | 0.01% | no change |